Episode
A conversation with Dr. Linda Cheek
Dr. Cheek is the founder of Doctors of Courage, and a leading physician advocate for opioid policy reform. She is ...
Protest In The Park – a conversation with organizer Bob Sheerin
We talk with Bob Sheerin, organizer of the Protest In The Park, to raise awareness for the upcoming rally. Protest ...
Protest In The Park – a conversation with organizer Nancy Seefeldt
We talk with Nancy Seefeldt, organizer of the Protest In The Park, to raise awareness for the upcoming rally. Protest ...
A conversation Dr. Zena Crenshaw-Logal, Executive Director of National Judicial Conduct and Disability Law Project, Inc.
Dr. Crenshaw-Logal has advocated for judicial reform nationally and internationally. Her work has been recognized throughout the United States and ...
A conversation with an addiction counselor, Kapil Nayar
When people discuss counterintuitive policies on opioids and addiction, they often use the phrase, "follow the money". We discuss the ...
A conversation with Jaz Singh, a former addict turned author
The journey into and out of addiction is deeply painful and personal. We applaud Jaz Singh for sharing his story ...
A conversation with a vaccine hesitant professional
We interview 'A', a financial professional who remains vaccine hesitant. We discuss the source of his hesitancy and how his ...
A conversation with Dr. Red Lawhern
Few in the chronic pain community carry as much gravitas as Dr. Red Lawhern, and even fewer have his reach ...
A conversation with Claudia Merandi
There are patient advocates and then there are those who galvanize an entire nation. Claudia Merandi is one such advocate, ...
A conversation with Dr. Salerian
Dr. Salerian was one of the first physicians targeted by the DEA in what has now become the systemic criminalization ...
Effective vaccine marketing campaign strategies
We discuss specific strategies vaccine marketing campaigns should implement to improve their effectiveness.
A conversation with Pharmacist Steve Ariens
We interview Pharmacist Steve Ariens, an active blogger who has become a leading voice over social media for patient rights ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
Does Online Therapy Work for Seniors?
-
Future of Miniature Medical Devices and Portable Health Care
-
Precision at the Molecular Level: How AI is Redefining Prostate Cancer Treatment
-
Retatrutide: The Weight Loss Drug Everyone Wants—But Can’t Officially Get
-
Observations From the Rx & Illicit Drug Summit
